ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,042Medicare Part D Prescriptions Filled, Including Refills

Rank: 6 out of 302

$439K Total Retail Price of All Prescriptions

Rank: 26 out of 302

316 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
86% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 316 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

11% of this provider’s 316 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

2% of this provider’s 7,427 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$55 was the average price of a prescription from this provider, compared to $100 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
SIMVASTATIN 472 418 1 3
OMEPRAZOLE 313 308 2 7
CARVEDILOL 287 263 3 19
LOVASTATIN 235 232 4 63
LEVOTHYROXINE SODIUM 225 217 5 9
LISINOPRIL 202 189 6 1
METFORMIN HCL ER 180 170 7 125
LISINOPRIL-HYDROCHLOROTHIAZIDE 176 176 8 53
METFORMIN HCL 168 157 9 13
BYSTOLIC 167 155 10 141
METOPROLOL SUCCINATE 145 133 11 6
AMLODIPINE BESYLATE 143 139 12 2
ZOLPIDEM TARTRATE 103 85 13 28
TRAMADOL HCL 100 100 14 16
CELEBREX 96 96 15 169
ATENOLOL-CHLORTHALIDONE 95 82 16 218
DONEPEZIL HCL 93 93 17 27
TAMSULOSIN HCL 91 70 18 41
LOSARTAN POTASSIUM 89 77 19 24
JANUMET 88 88 20 223
ATORVASTATIN CALCIUM 88 76 20 10
FUROSEMIDE 83 83 22 4
LANTUS 78 65 23 66
MELOXICAM 76 63 24 87
NEXIUM 75 75 25 47
AMLODIPINE BESYLATE-BENAZEPRIL 74 73 26 190
HYDROCODONE-ACETAMINOPHEN 72 57 S3 27 15
CRESTOR 71 71 28 34
ALENDRONATE SODIUM 68 68 29 49
PREDNISONE 64 64 30 31
DICYCLOMINE HCL 63 54 31 195
CLOPIDOGREL 62 60 32 23
ATENOLOL 60 50 33 20
LOSARTAN-HYDROCHLOROTHIAZIDE 57 57 34 90
FLUOXETINE HCL 57 44 34 105
LACTULOSE 55 55 36 89
INSULIN SYRINGE 54 52 37 193
DIOVAN HCT 53 53 38 117
PANTOPRAZOLE SODIUM 53 50 38 25
GLYBURIDE-METFORMIN HCL 51 51 R 40 145
BENAZEPRIL-HYDROCHLOROTHIAZIDE 51 46 40 289
LANTUS SOLOSTAR 50 33 42 157
PLAVIX 50 35 42 46
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.